Outcomes of Focused Ultrasound Thalamotomy in Tremor Syndromes
Objective: To report on the outcomes between tremor subtypes, Essential Tremor (ET), Dystonic Tremor (DT) and Parkinson Disease Tremor (PDT), following a unilateral Magnetic Resonance…The added value of accelerometric monitoring during thalamotomy
Objective: To quantify the clinical changes in tremor during the different stages of thalamotomy, and to investigate the relationship between intraoperative findings and clinical outcome.…The feasibility of MRI guided focused ultrasound for posttraumatic tremor with prior hemicraniotomy and skull defect
Objective: To assess the feasibility of MRgFUS lesioning in the context of prior hemicraniotomy Background: Targeted stereotactic lesioning, using MRgFUS, is an effective treatment option…Improved Tremor Response to Focused Ultrasound Thalamotomy
Objective: This study sought to determine if, when using four tract tractography (FTT) to target the decussating and non-decussating dentatorubrothalamic tracts (DRTTs), essential tremor (ET)…Anti-tremor efficacy of Nabiximols (JZP378) in a rat Model of essential tremor
Objective: To assess the effect of acute and subchronic oral administration of nabiximols (JZP378), a complex botanical cannabinoid drug mixture with Δ9-tetrahydrocannabinol (THC) and cannabidiol…Isolated vocal tremor: a case series
Objective: To describe the difficulties and limited treatment options for isolated vocal tremor. Background: Isolated vocal tremor is a unique phenotype of isolated focal tremor…Instability after MRIg-FUS thalamotomy: why does it appear?
Objective: To know the semiological characteristics and physiopathology of instability after thalamotomy with Magnetic Resonance image guided focused ultrasound thalamotomy (MRIg-FUS). Background: Gait instability is…KINETIC 2: An ongoing phase 2b, randomized, dose-response study of SAGE-324/BIIB124 for the treatment of essential tremor
Objective: KINETIC 2 (NCT05173012) is an ongoing, phase 2b, randomized, double-blind, placebo-controlled, dose-response study that aims to evaluate the efficacy, safety, and tolerability of SAGE-324/BIIB124…Design of a Phase 2 Study of Suvecaltamide in Moderate to Severe Parkinson’s Disease Tremor
Objective: Describe the design of a phase 2 study (NCT05642442) of a once-daily, extended-release formulation of suvecaltamide to treat moderate to severe Parkinson’s disease tremor…Patient experiences in essential tremor: mapping functional impacts to existing measures using qualitative research
Objective: To understand patient experience in essential tremor (ET), describe meaningful concepts related to treatment benefit, and compare concepts to existing clinical outcome assessments (COAs).…
- 1
- 2
- 3
- …
- 13
- Next Page »